Neurosense Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
EBITDA | -3,192 | -3,192 | -2,342 | -2,342 |
EBIT | -3,196 | -3,196 | -2,346 | -2,346 |
Net Income | -3,208 | -3,208 | -2,354 | -2,354 |
Free Cash Flow | -1,837 | -1,837 | -2 | -2 |
Cash | 166 | 166 | 666 | 666 |
Basic Shares | 25,560 | 25,560 | 25,402 | 25,402 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -22 | -97 | -89 | |
EBITDA | -11,109 | -9,877 | -9,638 | -12,229 |
EBIT | -11,125 | -9,899 | -9,659 | -12,318 |
Net Income | -11,125 | -10,210 | -10,107 | -12,340 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -7,679 | -10,138 | -8,383 | -7,656 |
Cash | 166 | 3,378 | 2,640 | 3,543 |
Basic Shares | 25,481 | 18,602 | 13,640 | 11,505 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | $0 |
2025-09-30 | -$0.04 |
2025-06-30 | -$0.19 |